Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Kappei Tsukahara"'
Autor:
Kazuto Yamazaki, Kenji Kubara, Satoko Ishii, Keita Kondo, Yuta Suzuki, Takayuki Miyazaki, Kaoru Mitsuhashi, Masashi Ito, Kappei Tsukahara
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 33, Iss , Pp 210-226 (2023)
Ornithine transcarbamylase (OTC) plays a significant role in the urea cycle, a metabolic pathway functioning in the liver to detoxify ammonia. OTC deficiency (OTCD) is the most prevalent urea cycle disorder. Here, we show that intravenously delivered
Externí odkaz:
https://doaj.org/article/48ee6ba359df4e7ca01a74bc5b65dc51
Autor:
Yuta Suzuki, Takayuki Miyazaki, Hiroki Muto, Kenji Kubara, Yohei Mukai, Ryuji Watari, Shinya Sato, Keita Kondo, Shin-ichi Tsukumo, Koji Yasutomo, Masashi Ito, Kappei Tsukahara
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 30, Iss , Pp 226-240 (2022)
mRNA and lipid nanoparticles have emerged as powerful systems for the preparation of vaccines against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. The emergence of novel variants or the necessity of cold chain logistics for
Externí odkaz:
https://doaj.org/article/4054f9f2cc084521a4b687b1b0017f6f
Autor:
Wataru Kawase, Daisuke Kurotaki, Yuta Suzuki, Hiroshi Ishihara, Tatsuma Ban, Go R. Sato, Juri Ichikawa, Hideyuki Yanai, Tadatsugu Taniguchi, Kappei Tsukahara, Tomohiko Tamura
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 25, Iss , Pp 708-715 (2021)
RNA interference-based gene silencing drugs are attracting attention for treating various diseases. Lipid nanoparticles (LNPs) are carriers that efficiently deliver small interfering RNA (siRNA) to the cytoplasm of target cells. Recently, we develope
Externí odkaz:
https://doaj.org/article/fa32f02bafe74885ab7b0205c2666905
Autor:
Tatsuma Ban, Masako Kikuchi, Go R. Sato, Akio Manabe, Noriko Tagata, Kayo Harita, Akira Nishiyama, Kenichi Nishimura, Ryusuke Yoshimi, Yohei Kirino, Hideyuki Yanai, Yoshiko Matsumoto, Shuichi Suzuki, Hiroe Hihara, Masashi Ito, Kappei Tsukahara, Kentaro Yoshimatsu, Tadashi Yamamoto, Tadatsugu Taniguchi, Hideaki Nakajima, Shuichi Ito, Tomohiko Tamura
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
IRF5 is a potential target for therapy in systemic lupus erythematosus (SLE). Here the authors show using mouse SLE-like models that genetic or chemical inhibition of IRF5 after SLE onset could be more effective than, or an add on for, currently util
Externí odkaz:
https://doaj.org/article/bdb59bea8b1b42119ff3a063d9c303ba
Autor:
Yoshikuni Tabata, Yoichi Imaizumi, Michiko Sugawara, Tomoko Andoh-Noda, Satoe Banno, MuhChyi Chai, Takefumi Sone, Kazuto Yamazaki, Masashi Ito, Kappei Tsukahara, Hideyuki Saya, Nobutaka Hattori, Jun Kohyama, Hideyuki Okano
Publikováno v:
Stem Cell Reports, Vol 11, Iss 5, Pp 1171-1184 (2018)
Summary: Parkinson disease (PD) is a progressive neurological disease caused by selective degeneration of dopaminergic (DA) neurons in the substantia nigra. Although most cases of PD are sporadic cases, familial PD provides a versatile research model
Externí odkaz:
https://doaj.org/article/fe1dd302708e4dc7827aa141f36e9904
Autor:
Kenji Kubara, Kazuto Yamazaki, Yasuharu Ishihara, Takuya Naruto, Huan-Ting Lin, Ken Nishimura, Manami Ohtaka, Mahito Nakanishi, Masashi Ito, Kappei Tsukahara, Tomohiro Morio, Masatoshi Takagi, Makoto Otsu
Publikováno v:
Stem Cell Reports, Vol 11, Iss 2, Pp 380-394 (2018)
Summary: Oncogenic KRAS mutations in hematopoietic stem cells cause RAS-associated autoimmune lymphoproliferative syndrome-like disease (RALD). KRAS plays essential roles in stemness maintenance in some types of stem cells. However, its roles in plur
Externí odkaz:
https://doaj.org/article/bec0e0806fec42e48f4d3ad662e1e2de
Autor:
Kazuto, Yamazaki, Kenji, Kubara, Yuta, Suzuki, Taro, Hihara, Daisuke, Kurotaki, Tomohiko, Tamura, Masashi, Ito, Kappei, Tsukahara
Publikováno v:
European Journal of Pharmaceutics and Biopharmaceutics. 183:61-73
Nucleic acid therapeutics have been utilized for gene regulation, and their recent advancement has led to approval of novel drugs for liver-related disorders. However, systemic extrahepatic delivery remains challenging. Here, we report newly designed
Autor:
Tatsuma Ban, Daisuke Kurotaki, Kappei Tsukahara, Hiroshi Ishihara, Tadatsugu Taniguchi, Hideyuki Yanai, Wataru Kawase, Tomohiko Tamura, Go R. Sato, Yuta Suzuki, Juri Ichikawa
Publikováno v:
Molecular Therapy. Nucleic Acids
Molecular Therapy: Nucleic Acids, Vol 25, Iss, Pp 708-715 (2021)
Molecular Therapy: Nucleic Acids, Vol 25, Iss, Pp 708-715 (2021)
RNA interference-based gene silencing drugs are attracting attention for treating various diseases. Lipid nanoparticles (LNPs) are carriers that efficiently deliver small interfering RNA (siRNA) to the cytoplasm of target cells. Recently, we develope
Autor:
Ryusuke Yoshimi, Tadatsugu Taniguchi, Hideyuki Yanai, Shuichi Suzuki, Akira Nishiyama, Hideaki Nakajima, Tadashi Yamamoto, Shuichi Ito, Kappei Tsukahara, Yohei Kirino, Noriko Tagata, Go R. Sato, Kenichi Nishimura, Tatsuma Ban, Hiroe Hihara, Masako Kikuchi, Akio Manabe, Masashi Ito, Kentaro Yoshimatsu, Yoshiko Matsumoto, Kayo Harita, Tomohiko Tamura
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-14 (2021)
Nature Communications
Nature Communications
The transcription factor IRF5 has been implicated as a therapeutic target for the autoimmune disease systemic lupus erythematosus (SLE). However, IRF5 activation status during the disease course and the effects of IRF5 inhibition after disease onset
Autor:
Kappei Tsukahara
Publikováno v:
Nihon yakurigaku zasshi. Folia pharmacologica Japonica. 157(1)
Eritoran (E5564) is Eisai's in-house discovered and developed investigational Toll-Like Receptor 4 (TLR4) antagonist created with natural product organic synthesis technology. It is a structural analogue of Lipid A, which is an activator of endotoxin